StoneRidge PMG Advisors, LLC’s Bristol-Myers Squibb BMY Stock Holding History

StoneRidge PMG Advisors, LLC’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$541K	Buy	+8,668	New	+$548K	0.38%	75

Other funds holding BMY

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Independent Franchise Partners London, United Kingdom $16.1B AUM 4.39% 1-Year Est. Return

StoneRidge PMG Advisors, LLC's BMY Position: Q3 2026 in Review

StoneRidge PMG Advisors, LLC opened a new position in Bristol-Myers Squibb (BMY) in Q3 2026: 8,668 shares worth $541K. The stake represents 0.38% of the portfolio and ranks #75 among its holdings.

2,253 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

StoneRidge PMG Advisors, LLC held 8,668 shares of Bristol-Myers Squibb worth $541K as of Q3 2026.
Bristol-Myers Squibb was a new StoneRidge PMG Advisors, LLC position in Q3 2026.
Bristol-Myers Squibb made up 0.38% of StoneRidge PMG Advisors, LLC's portfolio in Q3 2026, its #75 holding.
2,253 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on StoneRidge PMG Advisors, LLC's 13F filing for Q3 2026, filed 4 Nov 2026.